In This Issue pages highlight articles that the editors feel are particularly important by providing a short synopsis written in a language that can be understood by the nonspecialist. The purpose of this feature are two-fold: first, to call the attention of readers to important articles and, second, to enable all readers to grasp, easily and quickly, the significance of these papers. We believe that this initiative has been successful and, as a further service to our readers, provide below a compendium of these pages from the previous year, 2017. Each summary is accompanied by the corresponding citation, so that readers can easily find the entire article should they wish to read it. This remarkable anthology of outstanding articles attests to the diversity and depth of the work published in Circulation Research.
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Di Gregoli et al discover a potential new therapy for attenuating both atherosclerosis and aneurysm.
Abdominal aortic aneurysm (AAA) and atherosclerosis, the leading causes of cardiovascular disease, are both associated with increased inflammation and increased degradation of the extracellular matrix. These two pathological features are interrelated as inflammatory macrophages produce matrix metalloproteases (MMPs) and TIMPs that suppress MMP production. Indeed, previous studies have shown that macrophages with low TIMP-3 and high MMP expression are associated with unstable plaques. In liver cancer cells, TIMP-3 has been shown to be suppressed by microRNA miR-181b. Now, Di Gregoli and colleagues report that miR-181b is abundant in both atherosclerotic plaques and AAAs in humans, where it was found to be associated with decreased TIMP-3 expression. The team went on to show that blocking miR-181b activity in mice could retard the development of atherosclerotic plaques and attenuate aneurysm formation. Together, the results suggest that therapeutic suppression of miR-181b could be a novel treatment strategy for slowing or stopping progression of these two potentially deadly vascular conditions. Injury-induced limb ischemia is characterized by an initial neutrophil-driven inflammatory phase, followed by monocyte recruitment, angiogenesis, and ultimately resolution of inflammation. Activation of AMPK is thought to play an important role in hypoxia-induced angiogenesis. This enzyme is also known to be dysregulated in diabetes, which is associated with impaired vascular repair and limb ischemia. To examine the relationship between AMPK and limb ischemia more closely, Malik and colleagues studied mice lacking AMPKα2-the form of the enzyme linked to diabetes. They found that the recovery of blood flow after hind limb ischemia was markedly impaired in these animals, an effect that was fully recapitulated by the deletion of AMPKα2 specifically from myeloid cells (neutrophils). Deletion of AMPKα2, from endothelial cells, on the other hand, had no effect on recovery from ischemia. The team determined that the absence of AMPKα2 in neutrophils caused premature death of the cells, hindering subsequent monocyte recruitment and angiogenesis, while prolonging inflammation. In light of the results, the authors suggest that boosting AMPK in patients with diabetes may help to promote vascular repair and recovery from ischemic injury.
PDE2 in Arrhythmia and Contractile Function (p 120) 3
Vettel et al uncover a potential new strategy for preventing arrhythmia and preserving cardiac function in heart failure.
After myocardial infarction, the heart works harder to compensate for diminished function. However, this chronic increase in contractility results in hypertrophy, remodeling, and electromechanical dysfunction. As a result, lethal arrhythmias are a common cause of death in heart failure patients. The chronically elevated contractility is driven by prolonged cAMP-mediated β-adrenergic (β-AR) signaling. But heart failure is also associated with increased levels of phosphodiesterase 2 (PDE2), which could, under certain circumstances, degrade cAMP. Whether high PDE2 in heart failure is indeed a mechanism to counteract cAMP is unclear, however. Vettel and colleagues show that overexpression of PDE2 attenuates the rise in cAMP levels in heart cells undergoing chronic β-AR stimulation (to mimic heart failure). Furthermore, overexpression of PDE2 in transgenic mice lowered the animals' heart rates, and protected them from both cardiac function decline and lethal arrhythmias after myocardial infarction. Mice in which PDE2 was pharmacologically inhibited, on the other hand, exhibited increased heart contractility. Together, the results indicate that raising PDE2 levels could be a novel clinical approach for treating heart failure. 4 Majesky et al discover an unexpected origin of vascular progenitor cells.
SMC Reprogramming to Resident Progenitor Cells (p 296)
The adventitia, which forms the outer layer of blood vessels, is a collagen-rich tissue that has been traditionally thought to provide only structural support to the vessel. But recent research has shown that the adventitia contains a variety of dynamic cell types, such as the vascular progenitor cells. The origin of these progenitors was unclear, but Majesky and colleagues have now discovered, quite by accident, the source of at a least a subpopulation of these cells in mice. The team was studying how, after injury, the smooth muscle cells (SMCs) within the medial layer of blood vessels dedifferentiate and migrate to the innermost intimal layer. Unexpectedly, the team observed that SMCs also migrate to the adventitia, where they lost their SMC characteristics and gained stem cell markers. Further fate-mapping experiments confirmed that SMCs do indeed give rise to a subpopulation of adventitia-residing progenitors. These SMCderived progenitors were multipotent, giving rise to several cell types in vitro and in matrigel implants in mice. The team also found that the transition from SMC to progenitor was regulated by the transcription factor Klf4. Further studies are required to assess how these SMC-derived progenitors contribute to vascular homeostasis and pathology and how these cells could be targeted to treat vascular diseases, say the authors.
CD34
+ Cells for Post STEMI LV Dysfunction (p 324) 5 Nearly 20% of patients aged 45 and over who suffer a heart attack die within a year. Treatments to improve outcomes are desperately needed, and one possible therapeutic approach that has received much recent attention is coronary infusion of bone marrow-derived cells. Indeed, over 2600 patients have received autologous bone marrow cells in a variety of trials, but the outcomes have been inconsistent. It has been suggested that such unpredictable results may be due to variable bone marrow cell constituents, and that enriching for cells that express the stem cell marker CD34 may provide cell populations with greater clinical benefit. Indeed, a phase I trial of treatment with autologous CD34-positive bone marrow cells improved outcomes in heart attack victims. Now, Quyyumi and colleagues report that some patients enrolled in a randomized, double-blind phase II trial of CD34 cells also fared better than control subjects-with improved ejection fractions and reduced infarct sizes after 6 months. Improvement was seen in patients who were given a high-dose of cells (over 20 million), but low-dose recipients were indistinguishable from controls. The results confirm the safety of autologous CD34 + cell infusions and suggest that high doses of these cells may have some clinical benefit. Based on these results, the authors suggest that further randomized controlled trials should be performed to examine the efficacy of bone marrow-derived CD34 + cells.
Mesenchymal Stem Cells for Heart Failure (p 332) 6 Butler et al present the results of an intravenous stem cell therapy trial for nonischemic cardiomyopathy.
Nonischemic cardiomyopathy is a contractile dysfunction not caused by coronary artery disease (CAD) or myocardial infarction (MI). Nevertheless, as with CAD-or MI-induced heart failure, patients with nonischemic cardiomyopathy could potentially benefit from stem cell therapy. To date, cell therapies for any form of heart failure have been administered directly to the heart-because cell engraftment was considered necessary for clinical effect. However, some effects may derive from secreted factors, such as the anti-inflammatory factors produced by mesenchymal stem cells (MSCs Despite considerable progress in the treatment of coronary artery disease, there remain many patients for whom current therapies do not help. New approaches for such refractory angina patients are thus greatly needed. One potential treatment under study is transendocardial delivery of bone marrow stem cells. Indeed, recent studies have shown that such treatment reduces symptoms and improves quality of life in refractive angina patients. However, bone marrow contains a mixed population of cells, so it is possible that certain subpopulations of these cells are more effective than others in alleviating angina symptoms. CD133-positive bone marrow stem cells, for example, are known to have angiogenic potential, which might improve myocardial perfusion in patients. To test this idea, Wojakowski and colleagues administered transendocardial injections of CD133 + cells to patients with refractory angina. They observed no difference in myocardial perfusion or left ventricle ejection fraction between the test and control patients, but they suggest that with so few patients enrolled, the study might have lacked statistical power. Nevertheless, because the procedure was deemed safe, the authors suggest that a larger scale multicenter study is warranted.
Pediatric CPC-Derived Exosome Therapy (p 701) 9 Donor age and oxygen levels effect exosomes' reparative potential, say Agarwal and colleagues.
Stem and progenitor cells are being investigated for their potential to treat coronary artery disease (CAD). It is believed that these cells promote tissue repair via their paracrine effects on myocardial tissue or other noncardiac sites. Cardiac progenitor cells (CPCs), for example, release exosomes-small membrane-bound vesicles containing bioactive componentsthat have been shown in animal models to improve ventricular remodeling and promote healing after myocardial infarction. Evidence suggests that the effectiveness of stem cell therapies depends on oxygen levels and the age of the donor. To examine whether these factors also influence exosome therapies, Agarwal and colleagues isolated CPC exosomes from newborn babies, infants, and children undergoing heart surgery, and compared their reparative potential with and without hypoxic preconditioning. The team showed that, in rats suffering ischemia-reperfusion injuries, exosomes from newborns were the most effective at improving heart function. They also found that even though the potency of the exosomes diminished with increasing donor age, it could be restored by hypoxic preconditioning. The team went on to show that differences in the microRNA content of the exosomes were predictive of their effectiveness. Hence, it seems likely that microRNA analysis of exosomes from other cell types might reveal additional sources of exosome with high therapeutic potential.
Insulin Sensitivity and NO Availability (p 784) 10 Stimulation of endothelial nitric oxide synthase (eNOS) by insulin increases the production of nitric oxide (NO), which is a suppressor of atherosclerosis. Indeed, insulin resistance in type 2 diabetes is associated with both reduced production of NO and increased risk of atherosclerosis. To find out whether boosting insulin sensitivity in ECs could increase NO production and reduce atherogenesis, Viswambharan and colleagues genetically engineered mice to overexpress the human insulin receptor in ECs. Surprisingly, they found that even though insulin stimulation of the engineered ECs prompted Akt phosphorylation (a downstream mediator of insulin signaling), NO availability was reduced. Instead, insulin stimulation increased the activity of Nox2 NADPH oxidase, which in turn ramped-up production of damaging superoxide. The team then examined the EC-specific insulin receptor over-expression in atherosclerosis-prone mice, and found that the animals were even more prone to atherosclerosis than usual, with significantly accelerated plaque development in their aortas. The study suggests that upregulating insulin signaling may not be necessarily a desirable goal for diabetes treatment. 11 Lee et al describe a method for generating endothelial cells for therapy, disease analysis, and more.
ER71/ETV2-Mediated Reprogramming of HDF to Ecs (p 848)
Because endothelial cells (ECs) are critical for the repair and growth of blood vessels, researchers have been investigating possible ways to generate ECs for treating vascular disorders and injury. However, adult stem and progenitor cells are poor at endothelial transformation while embryonic or induced pluripotent stem cells, although better at endothelial cell conversion, carry a risk of tumorigenesis. Lee and colleagues, therefore, investigated an alternative idea of converting differentiated somatic cells into endothelial cells directly. Using human postnatal fibroblast cells, the team overexpressed a combination of 7 transcription factors known to be involved in endothelial cell differentiation. They succeeded in converting the fibroblasts into cells whose morphology and gene expression resembled endothelial cells and then, by a process of elimination, discovered that just one of these transcription factors-ETV2-was sufficient for the conversion. The reprogrammed endothelial cells were capable of contributing to vessel formation and recovery from hind limb ischemia in mice. Based on these findings, the authors suggest that direct reprogramming of differentiated fibroblasts into endothelial cells could be used for autologous cell therapies as well as personalized disease studies and drug testing.
ATF6 Links ER Stress and Oxidative Stress (p 862)
12
Transcription factor ATF6 mitigates oxidative stress as well as ER stress, report Jin et al.
The ER stress response of a cell becomes activated when unfolded or misfolded proteins accumulate in the ER. Activating transcription factor 6 alpha (ATF6) is upregulated early in the response and shuttles into the nucleus to activate ER stress genes, which then work to resolve the folding problems. Recently, however, ATF6 has also been shown to protect the heart against ischemia/reperfusion damage. To investigate the mechanism behind this protective effect, Jin and colleagues examined cardiomyocytes lacking ATF6. They showed that on induction of ischemia-reperfusion, the cells produced unusually high levels of reactive oxygen species. ATF6 overexpression relieved this effect. Gene expression analysis revealed that ATF6 activated not only ER stress related genes, but also genes encoding antioxidant proteins, including catalase. The team then showed that when mouse hearts were subjected to ischemia-reperfusion, genetic deletion of ATF6 worsened infarct size and heart miRNA Mimics for Cardiac Regeneration (p 1298) 16 Lesizza et al inject microRNAs into the heart to boost cardiac regeneration.
MicroRNAs (miRs) regulate all manner of cellular and physiological processes, including practically every aspect of cardiovascular biology. For example, at least 40 miRs have been found to promote various steps in cardiomyocyte proliferation. Two of these proliferation-promoting miRs-miR-5903p and miR-199a-3p-when packaged into viral vectors and injected into mouse hearts have been shown to contribute to tissue regeneration after myocardial infarction. While these results were encouraging, the use of viral vectors to deliver miRs has inherent safety and efficacy concerns that hinder the chances of such treatments reaching the clinic. With this in mind, Lesizza and colleagues examined whether a more desirable delivery method could also provide pro-proliferative effects in mice. The team injected miR-199a-3p or miR-5903p combined with lipid-based transfection reagents into the hearts of mice that had been subjected to experimental myocardial infarction. They found that while left ventricle ejection fraction steadily deteriorated in control mice, it was better preserved in animals that received the miRs. MiR recipients also had reduced infarct sizes and evidence of increased cardiomyocyte proliferation. These results suggest that in vivo lipid-based transfection of miRs is a therapeutic strategy ripe for further optimization.
3D-Printed Scaffolds for Engineered Myocardium (p 1318) 17
Gao et al use cutting-edge 3D printing technology to create artificial matrices for myocardial patches.
Cardiac cells derived from human-induced pluripotent stem cells (iPSCs), when injected into the hearts of large animals, have been shown to improve recovery from myocardial infarction. Because cell engraftment is not optimal, however, researchers are also using iPSCs to create embeddable tissue patches. Such engineered tissues may be enhanced by incorporating an extracellular matrix (ECM)-like scaffold to which the cells can adhere. To this end, Gao and colleagues turned to state-of-the-art printing-specifically multiphoton-excited 3D printing, which can produce features smaller than a micron. Using a mouse myocardial ECM as the template, the team printed their artificial version using a gelatin polymer, and on to it seeded human iPSC-derived cardiac cells. After just 1 day of culture, the cells were beating synchronously, and after a week the tissue patch exhibited both functional electrophysiology and cell-to-cell communication. Incorporating the patches into the hearts of mice that had suffered myocardial infarctions led to improved heart function, reduced infarct size, increased vasculogenesis, and reduced apoptosis, compared with control animals. Although it is not yet clear whether the tissue patches electromechanically integrate with the heart, the results encourage further development of this potential therapeutic technique. e99
Meta-Analysis of Cell Therapy for PAD (p 1326)
18
A meta-analysis suggests autologous cell therapy can improve prognosis of chronic limb ischemia, say Rigato et al.
Peripheral artery disease (PAD), in which the blood vessels narrow due to build-up of calcium or fatty deposits, is a common complication of atherosclerosis and is estimated to affect ≈10% of people aged 40 and over. For some PAD sufferers, the condition may develop into chronic limb ischemia (CLI), and while some CLI patients may be treated with revascularization procedures, many face amputation. Cell therapies aimed at promoting vasculogenesis in such patients have been extensively investigated, but trials have drawn inconsistent conclusions. Rigato and colleagues, therefore, conducted a meta-analysis of autologous cell therapy trials for CLI. Their investigation included nonrandomized and uncontrolled trials, but their most important findings focused on randomized controlled trials (RCTs), which accounted for more than a third of the patients treated. Within these RCTs, the team discovered that intra-muscular or intra-arterial cell injection reduced the risk of amputation by 37%, improved amputation-free survival by 18%, and improved wound healing by 59%. The authors suggest that further trials are warranted, but also argue that, since amputation may be the only option for patients enrolled in such trials, clinical equipoise may not be appropriate.
Flow-Induced Lymphatic Growth (p 1426) 19 Choi et al discover how tissue fluid flow prompts lymphatic vessel development.
A fully functional lymphatic vasculature is essential for draining interstitial fluid and preventing tissue edema. Interestingly, research suggests that in the growing embryo the very presence and flow of fluid within tissues prompts lymph development.
To understand how tissue fluids generate their own drainage system, Choi and colleagues focused on lymphatic endothelial cells (LECs), which give rise to the vessels. They showed that a steady laminar flow of culture medium over LECs, but not blood vessel ECs, induced these cells to proliferate. They also showed that proliferation-promoting transcription factors were upregulated in flow-treated LECs and that blocking the actions of these factors reduced flow-induced proliferation. Laminar flow is known to induce calcium influx in LECs, and the team went on to show that a plasma membrane calcium channel, called CRAC, was an integral link between laminar flow and proliferation, a link supported by the observation that knocking down a key component of the channel (a subunit called ORAI1) prevented the flow-activated proliferation of LECs. Moreover, in mice lacking functional ORAI1, lymph vessel density was reduced. Together, these results provide new insights into the development of the lymphatic system and may shed light on how, in certain lymphatic disorders, this process goes awry.
Transcellular Solute Transport in Lymphatics (p 1440)
20
Solutes travel to lymph vessels both through and between lymphatic endothelial cells, report Triacca et al.
The interstitial fluid in the body is continuously drained via lymphatic vessels, accumulating first in the nodes before eventually returning to the blood. This draining process has been thought to be largely passive-the result of hydrostatic pressure differences between the tissues and lymph vessels. Indeed, fluid flow into a vessel's lumen was thought to occur primarily between the lymphatic endothelial cells (LECs), which form the vessel lining. However, there is little direct evidence to support this view, and recent evidence suggests that solute-filled vesicles could also transit across the LEC cytoplasm. To find out, Triacca and colleagues injected fluorescent albumin into the dermis of mouse ears and observed the protein's passage to the lymph. They found that the albumin entered LECs, and in vitro studies confirmed that the protein was transported via vesicles. The team went on to show that solute uptake via this transcellular pathway was boosted by both increased fluid flow and the presence of inflammatory molecules. These results indicate that, in addition to passive paracellular transport, solute passage to the lymph can be actively controlled by LECs-a finding that could impact our understanding of the maintenance of tissue homeostasis, as well as the resolution of inflammation. 21 Arpino et al's close examination of regenerating microvessels reveals flaws.
4D Analysis of Regenerative Angiogenesis (p 1453)
After an ischemic injury, the affected tissue undergoes rapid vasculogenesis. But it is unclear whether the newly regenerated vessels fully resemble the anatomy and function of normal vessels. To address this question, Arpino and colleagues decided to take a closer, more high-resolution look. Using a combination of intravital and confocal microscopy, they examined the regrowth of microvessels after hind limb ischemia in mice. They found that, although the vessels regenerated rapidly and robustly in the animals' legs, the branching architecture of the vessels was aberrant, and the transit of red blood cells through the capillaries was slow, and disorderly, and did not respond adequately to local hypoxia. The researchers also found that smooth muscle cells surrounding the vessels did not form a continuous uniform layer as expected. These abnormalities persisted for several months after injury. The authors conclude that future therapeutic revascularization strategies must achieve more than just vessel regrowth if they are to restore tissue oxygenation in patients with ischemia.
Cardiomyopathy TALEN Knockout Library (p 1561) 22 Karakikes et al edit genes in induced pluripotent stem cells to examine cardiovascular disease mechanisms.
Although many genetic mutations that cause inherited cardiomyopathies and congenital heart diseases have been identified, the molecular mechanisms underlying these conditions remain poorly understood. However, recent developments in gene editing and the generation of induced pluripotent stem cells (iPSCs) could change that. Karakikes and colleagues have now created a panel of gene editing constructs designed to target and disrupt 88 different genes associated with cardiovascular diseases. Introducing these individual constructs into human iPSCs and then differentiating the cells into cardiomyocytes should enable researchers to observe how a given mutation affects myocardial development. As proof of principle, the team examined iPSCs in which the TBX5 gene had been homozygously deleted to model Holt-Oram syndrome-a condition characterized by heart defects and limb abnormalities. After cardiomyocyte differentiation, the cells exhibited abnormal action potentials, and the team was able to identify novel genes and pathways targeted by the TBX5 transcription factor. In separate experiments, the team corrected a mutation associated with dilated cardiomyopathy in iPSCs derived from a patient with the condition.
GNB2 Is a Disease Gene for Familial SND and AVB (p e33) 23 Stallmeyer et al discover a new mutation causing sinus node and atrioventricular conduction dysfunction. e101
Sinus node dysfunction is characterized by fainting, dizziness and palpitations, and by tachycardia, brachycardia, and impaired or blocked atrioventricular conduction (AVB). The condition is progressive and thus manifests most often in elderly patients, but can also occur early in life, suggesting inheritance of a genetic defect. Although some causative mutations have been identified, in most cases of familial disease, the underlying cause is unknown. Now, from studying 25 members of a family with SND and AVB, Stallmeyer and colleagues have identified a new mutation. Genetic linkage analysis of affected and unaffected family members first narrowed the search to a region on chromosome 7 containing 272 genes. Sequencing of these genes revealed just 1 nucleotide change that both had a predicted functional consequence and was present in all affected family members while being absent from all unaffected members (as well as from 10 000 control individuals). This mutation disrupted a gene encoding a G-protein called GNB2, which the team found to be associated with abnormally enhanced activity of the GIRK potassium channel. Taken together, these results suggest that GNB2 and GIRK play an important regulatory role in the physiology of the sinus and atrioventricular nodes and that these proteins could be potential targets in developing treatments for sinus node dysfunction 25 Luo et al generate synthetic stem cells for cardiac therapies.
Evidence indicates that the administration of stem cells, such as mesenchymal stem cells (MSCs), to patients with damaged hearts can improve myocardial function. It is currently believed that such reparative effects of MSCs are largely due to secreted factors. However, treating patients directly with such factors has been unsuccessful-possibly because the effects of the factors could not be sustained. Luo and colleagues reasoned that if such factors were enclosed in protective packaging, they might prove more effective. To find out, the team loaded MSC secretome proteins onto particles of poly(lactic-co-glycolic acid)-a biocompatible polymer that protects cytokines from degradation-and coated these particles with MSC membranes. Like regular MSCs, the repackaged synthetic MSCs (synMSCs), when cocultured with neonatal rat cardiac myocytes, synMSCs induced proliferation and contractility. And when given to mice with myocardial infarction, the reduced infarct size increased ventricle wall thickness and increased blood vessel density. Given these similar results, unpackaging and repackaging MSCs may seem unnecessary, but the defined composition of the synMSCs should provide a more uniform and predictable medication than cell-based approaches. Furthermore, the synMSCs exhibited superior stability to MSCs-suggesting synMSCs may be useful as an offthe-shelf treatment option. Monocyte Patrolling in Arteries (p 1789) 27 Quintar et al investigate monocyte patrolling behavior in arteries.
20-HETE-GPR75
Unlike classical inflammatory monocytes, nonclassical monocytes patrol blood vessel endothelium scavenging dead cells and debris. These patrolling cells were discovered in the microcirculation, and all subsequent studies have focused on these vessels. As a result, with the exception of monocyte recruitment to atherosclerotic plaques in arteries, little is known about monocyte-endothelial interactions in large vessels. Using a recently developed imaging technology, called intravital live cell triggered imaging system (ILTIS), Quintar and colleagues have now been able to monitor nonclassical monocytes in the arteries of healthy, hyperlipidemic, and atherosclerotic mice. They found that monocytes patrol healthy arteries-with each patrolling session lasting 5 to 10 minutes. In 2 different mouse models of hyperlipidemia, the patrolling behavior of these cells was increased by 8-to 9-fold. In atherogenic mice, patrolling increased by 22-fold, with each patrol lasting longer and proceeding more slowly. The number of patrolling cells directly correlated with the extent of endothelial damage, and mice with deficient patrolling monocytes exhibited greater atherosclerotic lesions. Together, the results suggest that the patrolling cells have a protective role in arteries and raise the possibility that therapeutically increasing monocyte patrolling behavior could help in reducing atherogenesis.
Cardiac Myocyte Maturation In Vivo (p 1874) 28 Guo et al create a CRISPR system for analyzing gene function during cardiomyocyte maturation.
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The ability to differentiate stem cells into cardiomyocytes opens an array of research possibilities from disease modeling to regenerative therapies. However, the process is not optimal, in part because the cardiomyocytes generated by the process do not reach full maturity. To examine factors that control full post-natal maturation of myocytes, and how these could be leveraged to improve stem cell differentiation, Guo and colleagues developed a CRISPR/Cas 9-based system for mutating genes of interest in the hearts cells of newborn mice. They attached fluorescent tags to mutated cells, allowing them to follow resulting phenotypic changes in the context of the developing heart. Using this system, they targeted 9 genes with potential roles in the development of transverse tubules (T-tubules), which are essential for excitation-contraction coupling and are hallmarks of fully matured cardiomyocytes. They found that 1 gene (Jph2), previously implicated in T-tubule development, was actually minimally involved in the process, instead playing a role in T-tubule stabilization, while another (Ryr2) was critical for T-tubule formation. The new system should improve gene function analyses not only during cardiomyocyte maturation but other aspects of cardiomyocyte biology too.
Nampt and Thoracic Aortic Degeneration (p 1889)
29
Nampt is critical for aortic smooth muscle health, report Watson et al.
Although built to withstand continuous hydrodynamic stress, the aorta, like all tissues, degenerates over time.
Chronic diseases such as atherosclerosis and hypertension quicken this degeneration, and, if severely weakened, the aorta can dilate leading to the formation of an aneurysm or even rupture. Smooth muscle cells (SMCs) that surround the aorta effectively fix minor damage, but this ability dwindles with cell age. It has been found that the enzyme Namptwhich produces the cell metabolism and vitality factor nicotinamide adenine dinucleotide (NAD + )-can extend the life of SMCs in vitro and that levels of the enzyme decline as SMCs senesce. Now, Watson and colleagues show that Nampt is essential for maintaining SMC health and aortic integrity in vivo as well. They found that mice genetically engineered to lack Nampt specifically in their SMCs were more prone to hypertension-induced aortic dilation and rupture, and that their SMCs were more prone to senescence and DNA damage. Furthermore, the team showed that patients with dilated ascending aortopathy had lower levels of Nampt, and correspondingly increased DNA damage in their aortic SMCs. The Nampt gene promoter region was also epigenetically repressed in these cells. Together, these results show Nampt is critical for aortic health and suggest that the enzyme may be involved in the pathogenesis of aortic aneurysms. 30 Methodological rigor in preclinical research has not improved, say Ramirez et al.
Methodological Rigor in Preclinical Research
Irreproducible scientific results raise particular concerns for translating preclinical research into human studies. To improve preclinical methodology, and therefore the chances of reproducibility, the National Institute of Neurological Disorders and Stroke (NINDS), in 2012, published guidelines that outlined the following minimal reporting requirements: randomization of animals, blinding of investigators, sample size estimation (the computation of the appropriate sample size for the study), as well as data handling. The American Heart Association (AHA) journals unanimously agreed to comply with these guidelines, but whether this has led to an improvement of standards is unknown. To find out, Ramirez and colleagues reviewed preclinical cardiovascular studies in AHA journals from 2006 to 2016. They found that just 21.8% of studies reported randomization, 32.7% reported blinding, and just 2.3% reported sample size estimation. Significantly, with the exception of the journal Stroke, there had been no increases in these percentages over the 10 years, or since the NINDS report. Moreover, papers that did adhere to the guidelines were no more highly cited than those that did not. The accumulation of calcium deposits in major arteries is associated with aging and with atherosclerotic plaque formation. Once thought to be a passive process, vascular calcification is now known to occur via the same mechanism as bone formation, suggesting that the balance of osteoblastic (boneforming) and osteoclastic (bone resorptive) activity becomes somehow skewed. Osteoclasts derive from the same lineage as monocytes and macrophages. And since such cells are abundant in plaques, Chinetti-Gbaguidi and colleagues decided to examine human plaque macrophages for their osteoclastic activity. The researchers specifically focused on cells surrounding calcium deposits and found that, while these macrophages expressed the osteoclastic marker CA2, their expression of a key osteoclastic enzyme involved in bone resorption was abnormally low, as was their bone resorptive activity in vitro. These osteoclast-like macrophages were of the alternative, or M2, phenotype, which tends to be associated with antiinflammatory mechanisms and plaque stability. The discovery of these cells with deficient osteoclast behavior, however, suggests that M2 macrophages are not always atheroprotective. The findings also indicate that therapeutic modulation of the osteoclast-like cells may reduce plaque calcification and slow atherosclerosis progression.
Flow and Neutrophils Mediate Superficial Erosion (p 31) 32
Franck et al investigate superficial plaque erosion in a mouse model.
The rupturing of atherosclerotic plaques is a major cause of heart attacks, but in recent years, because of the increased use of statins, and other lifestyle and medical interventions, the incidence of plaque rupture is reducing, while the occurrence of superficial plaque erosion with consequent thrombus formation is on the rise. Despite plaque erosion becoming an increasing concern, little is known about its underlying mechanisms. To investigate, Franck and colleagues recapitulated eroded plaques in the carotid arteries of live mice. The team fed atherosclerosis-prone mice a diet of chow rather than high-fat so as to limit lipid and foam cell content of plaques. Then they induced small endothelial injuries that mimicked erosion-prone plaques of human arteries. In these mice, the team showed that there was plaque erosion when blood flow perturbations caused endothelial cell activation, neutrophil accumulation, and consequent endothelial cell death. Neutrophil accumulation was found to be critical to the process, because deletion of the TLR2 receptor on endothelial cells both prevented neutrophil adherence and thrombus formation. The development of this mouse model of superficial plaque erosion will be a valuable tool in the study of this increasingly important pathological process.
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CETP Protein Truncating Variants and Risk for CHD (p 81) 33
People with truncated cholesteryl ester transfer protein are at lower risk of heart disease, report Nomura et al.
Cholesteryl ester transfer protein (CETP) transfers lipids between high-density lipoproteins (HDL) and low-or very-lowdensity lipoproteins (LDL or VLDL)
. In genetic studies, it has been shown that individuals with naturally low CETP expression are at lower risk of coronary heart disease (CHD). This finding has prompted research into pharmacological inhibition of CETP to increase HDL and reduce atherosclerosis. However, trials of small molecule CETP inhibitors have failed to show reduced CHD risk. In addition to people with low levels of CETP, some individuals have truncated versions of the protein, and Nomura and colleagues considered that such truncations might be more akin to pharmacological protein inhibition. The team examined over 80 000 individuals who had or did not have truncated CETP and found that, just like people with low CETP expression, those with truncated CETP were at significantly lower risk of developing CHD. Such individuals also had higher plasma HDL and lower LDL and triglycerides. It is not clear why pharmacological inhibition does not recapitulate genetic deficiency of CETP, but the authors suggest, among other things, possible off-target effects of the small molecules, or limited statistical power of the trials, both of which deserve further investigation. 34 Monsanto et al devise a straightforward protocol for isolating key stem cell types from human heart tissue. and CPCs that display their expected and distinct morphologies, growth kinetics, gene expression profiles, and propensities for particular fates. The approach will, therefore, allow researchers to study the 3 cell types either individually or in combination, to determine how each contributes to heart regeneration, and to devise ways to best promote such regeneration in patients after heart injuries.
Concurrent Isolation of Human Cardiac Stem Cells (p 113)
EZH1 Promotes Heart Regeneration (p 106)
35
Epigenetic factor EZH1 promotes myocardial regeneration, report Ai et al.
Adult myocardium has limited regenerative potential, such that injuries to the heart result in scarring and reduced function. The hearts of newborn mice, by contrast, have incredible regenerative power, though this ability dwindles rapidly after the first few days of life. This loss of regenerative potential is accompanied by alterations to the epigenetic landscape of the cardiomyocytes. It has been shown, for example, that levels of the 2 catalytic subunits of a major chromatin silencing factor-polycomb repressor complex 2 (PRC2)-decrease in cardiomyocytes coincident with decreasing regenerative potential. Ai and colleagues examined the roles of these 2 subunits-called EZH1 and EZH2-in mouse heart regeneration and showed that genetic deletion of Ezh1, but not Ezh2, in cardiomyocytes prevented heart regeneration after injury in newborn mice. Furthermore, over-expression of EZH1, but not EZH2, could prolong the neonatal regeneration period, as myocardial infarction at postnatal day 10 was still repairable. This prolongation of regenerative potential was accompanied by increased expression of genes involved in cardiac growth and development, the team showed. Together, the results suggest that manipulations of EZH1 in adult cardiomyocytes may restore the regenerative capacity of these cells to a more youthful setting. 36 Troupes et al identify a potential therapeutic target for the treatment of heart failure.
Role of STIM1 in Contractile Dysfunction (p 125)
Cardiac hypertrophy-the enlargement of the heart and its cells-is associated with aberrant calcium handling in cardiomyocytes, which increases a patient's risk of arrhythmia and heart failure. Stromal interaction molecule 1 (STIM1) is a protein that, in nonexcitable cells, mediates calcium influx via channel protein Orai. In cardiomyocytes, calcium influx largely occurs via L-type calcium channels, so the role for STIM1 and Orai, which are also expressed in these cells, is unclear. STIM1-Orai activity is increased during hypertrophy, however, which prompted Troupes and colleagues to examine the contribution of these factors to the condition. Using a large animal model (cats), they showed that during cardiac hypertrophy, STIM1 expression and activity was increased and calcium handling was altered (calcium sparks were more numerous and action potentials were longer). Furthermore, over-expressing STIM1 in normal cat cardiomyoctyes recapitulated these problems, while blocking Orai activity prevented them. Together, the results indicate that increased calcium influx mediated by increased STIM1-Orai activity directly contributes to the pathology of hypertrophy and that targeting STIM1-Orai could be a potential strategy for reducing the risk of arrhythmia and heart failure in hypertrophy patients.
DRP1
Regulates Cardiovascular Calcification (p 220) 37 Mitochondrial regulator DRP1 promotes vascular calcification, report Rogers et al.
Blood vessel calcification is associated with adverse hemodynamics and cardiovascular conditions. Once believed to be a passive process of aging, it is now known that calcification involves the active differentiation of smooth muscle cells (SMCs) and valve interstitial cells (VICs) into bonelike cells (osteoblasts). Many of the biological processes related to vessel calcification-such as cell differentiation, apoptosis, and calcium homeostasis-involve mitochondrial dynamics, and it has been shown that mutations to the mitochondrial regulator dynamin-related protein 1 (DRP1) are associated with calcification of heart tissue in mice. Rogers and colleagues have examined the potential link between DRP1 and calcification in humans. They found that in human carotid artery plaques and in calcified valve tissue-from patients undergoing aortic valve replacements-DRP1 staining was elevated in regions of calcium deposition. Furthermore, DRP1 levels were also high in cultures of human SMCs and VICs undergoing osteoblast differentiation, and inhibition of DRP1 attenuated both SMC and VIC calcification. The findings suggest that human DRP1 promotes vascular calcification and that this condition may be prevented or attenuated by therapeutic inhibition of DRP1.
CD8α
+ Dendritic Cells, IL-10, and Atherosclerosis (p 234) 38 
Haddad et al identify the necrosis sensor DNGR1 as a potential therapeutic target in atherosclerosis.
The accumulation of apoptotic cells and necrotic debris within atherosclerotic plaques is associated with both chronic inflammation and an increased risk of plaque rupture. But how the insufficient clearance of dead cells leads to inflammation in atherosclerosis is not well understood. Haddad and colleagues hypothesized that the dendritic cell NK lectin group receptor-1 (DNGR1), which is known to recognize molecules released from dying cells, might be involved in this process. To investigate this possibility, the team examined atherosclerosis-prone mice that lacked DNGR1-either fully or specifically in bone marrow cells-and showed that these animals had reduced plaque sizes and slower atherosclerosis progression. DNRG1 deletion also led to a dramatic increase in the levels of IL-10-an anti-inflammatory factor-with a concurrent decrease in the number of macrophages within plaques. The team also found that in mice whose bone marrow cells lacked both DNGR1 and IL-10, the protective effects of DNGR1 deletion alone were completely abolished. Altogether, these results indicate that DNGR1, via suppression of IL-10, serves to promote atherosclerosis, and that this necrosis-sensing factor might be a novel therapeutic target for promoting plaque stabilization and slowing atherogenesis.
PVM and Aβ-Induced Neurovascular Dysfunction (p 258) 39 Perivascular macrophages mediate amyloid-β driven neurovascular dysfunction, say Park et al.
Alzheimer disease (AD) is the most common form of dementia in the elderly. This debilitating condition is characterized by the intracellular aggregation of tau proteins and the extracellular accumulation of amyloid-β (Aβ) peptides. It is thought that cerebral vascular dysfunction plays a role in the progression of AD and that Aβ may be responsible, at least in part, for this dysfunction. Indeed, Aβ has been shown to disrupt vascular endothelial function and prevent the normal increase in blood flow seen during brain activity. Binding of Aβ to the receptor CD36 with downstream production of reactive oxygen species (ROS) mediates the vascular dysfunction, but the particular cells involved were unknown. Park and colleagues now suggest that perivascular macrophages may be the culprits. They found that specific depletion of these cells in the brains of AD model mice reduced the oxidative stress and vascular dysfunction caused by Aβ. They obtained similar results by depleting either CD36 or Nox2 (the enzyme responsible for ROS production) specifically from perivascular macrophages. These results confirm the involvement of CD36 and Nox2 in Aβ driven neurovascular dysfunction, identify perivascular macrophages as the cellular mediators, and suggest that therapeutic manipulations of these cells may ameliorate brain dysfunction in AD patients. 40 Cheng et al discover that unleashing inflammatory signaling can, paradoxically, reduce atherosclerosis. Atherosclerosis develops when fatty deposits in the blood vessels cause endothelial cell (EC) activation and leukocyte recruitment, with subsequent inflammation, mediated largely by the activation of NF-κB signaling. The microRNA miR-146a is known to suppress NF-κB, and injection of miR-146a into atherosclerosis-prone mice has been shown to suppress plaque development. However, the role of NF-κB is complex: suppression of this transcription factor in ECs reduces atherosclerosis; while its suppression in macrophages increases lesion formation. Indeed, Cheng and colleagues have now found that removing miR-146a (thus activating NF-κB), specifically in bone marrow cells (BMs), reduced atherosclerosis in mice, while in ECs miR-146a removal increased atherosclerosis. Paradoxically, while miR-146a depletion in BMs reduced plaque burden in the animals, there was an increase in systemic inflammatory signaling, which, the team suggests, appears to cause hematopoietic cell exhaustion. Indeed, the miR-146a depletion in BMs seems to suppress atherogenesis by over-activating the BMs so much they essentially burn out. In agreement with previous work, these results suggest that a general therapeutic augmentation, rather than suppression, of miR-146a may slow atherosclerosis. 41 Liu et al analyze the early stages of in vitro human cardiomyocyte differentiation.
MiR-146a Regulates Atherogenesis (p 354)
Omics Profiling of Early Cardiac Differentiation (p 376)
The ability to differentiate human induced pluripotent stem cells (hiPSCs) and embryonic stem cells (hESCs) into cardiomyocytes (CMs) in vitro is valuable for the study of heart cell development, disease processes, and other myocardial systems. A thorough understanding of the molecular details of this in vitro differentiation is essential, but while transcriptional regulation at late stages of the process has been well studied, analysis of earlier phases has been lacking. Liu and colleagues used both RNA sequencing and chromatin accessibility assays to determine the transcription and chromatin dynamics throughout CM differentiation. Using 2 hiPSC lines and 2 hESCs lines, the team found that patterns of both transcription and chromatin accessibility were highly similar between the 4 cell lines, and identified a number of novel factors specific for particular stages. They also showed that one such factor, ZEB1, upregulated at the cardiac mesoderm stage, was required for early differentiation-knock down of ZEB1 caused a number of essential CM differentiation factors to be downregulated. These results provide novel insights into the early stages of in vitro cardiomyoctye differentiation that will help to frame future investigations into heart development and disease.
hMSC Effects on Contraction and Arrhythmogenesis (p 411) 42 Mayourian et al distinguish between the different effects of mesenchymal stem cells on heart tissue.
Human mesenchymal stem cells (hMSCs) have therapeutic potential for the treatment of damaged heart tissue. But despite encouraging preclinical results, trials with hMSCs have provided modest benefits, at best. To improve such therapies, a thorough understanding of the interactions between MSCs and cardiomyocytes is essential. It has been suggested that the benefits come mainly from paracrine signaling. Indeed, hMSC-conditioned media can modulate ion channel activity and action potentials in rodent cardiomyocytes. MSCs can also form gap junctions with cardiomyocytes, however, and these heterocellular couplings might also impact cardiomyocyte physiology. Using computational modeling, together with studies of human-engineered cardiac tissue, Mayourian and colleagues have begun resolving the independent effects of paracrine signaling and heterocellular coupling. They showed that paracrine signaling had a greater ability to increase contractility of cardiac tissue than heterocellular coupling and was, in fact, protective against the potential proarrhythmic effects of such coupling. The research, which also included proteomic analyses of MSC and cardiac tissue interactions, provides greater insight into how the stem cells influence the heart and suggests that future studies into how paracrine signaling improves cardiac contractility could lead to more effective therapies.
Role of Hey2 in Transmural Electrical
Patterning (p 537) 43 Veerman et al determine the likely effect of a Brugada syndrome risk allele.
Brugada syndrome is characterized by abnormal electrical signals in the heart and a heightened risk of sudden death. A genome-wide association study (GWAS) has identified a Brugada-linked single nucleotide polymorphism (SNP) at the genetic locus 6q22.31. This SNP lies close to the gene for transcription factor HEY2; however, whether HEY2 contributes to Brugada syndrome is unclear. Veerman and colleagues examined gene expression data from 190 human left ventricle samples and found that, of 8 genes in the 6q22.31 region, only HEY2 showed significant association-increased expression-with the Brugada risk allele. Further, genome-wide coexpression analyses showed that, of 15 617 genes examined, the expression of KCNIP2, which encodes an ion channel subunit, was most tightly correlated with the expression of HEY2. The team went on to show that myocardial expression of KCNIP2 was lower in HEY2-deficient mice than in wild-type animals, suggesting that HEY2 regulates KCNIP2. Indeed, these HEY2-deficient animals exhibited abnormal electrical patterning in the ventricle wall consistent with altered ion channel function. The results indicate that high HEY2 expression increases the risk of Brugada syndrome and highlight the utility of expression analyses for uncovering potential functions of GWAS identified loci. 44 Transient Notch activation causes long-term electrophysiological problems in the heart, say Qiao et al.
Notch and Sick Sinus Syndrome (p 549)
Cell-cell signaling via transmembranous Notch proteins is essential for a variety of developmental processes, including the formation and function of several cardiovascular structures and systems. In adult mouse heart cells, Notch signaling is generally quiescent, but after an injury-such as a myocardial
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infarction-Notch is transiently reactivated, which in turn leads to altered ion channel expression and aberrant electrical properties. Qiao and colleagues have now examined the effects of such transient Notch reactivation in more detail. They found that in mice subjected to transient atrial Notch activation, there was significant heart rate slowing, sinus pausing, and dysregulation of sinus node and atrial conduction factors. Furthermore, these transcriptional and electrophysiological changes were sustained long after Notch signaling had returned to normal. Heart rate, for example, remained low for a year. Because cardiac injuries can predispose patients to atrial arrhythmias, the researchers suggest that a thorough understanding of the long-term cardiac effects of transient, injuryinduced Notch activation may reveal pathways and factors that could be targeted for antiarrhythmic interventions.
Inhibition of Meg3 Prevents Cardiac
Remodeling (p 575) 45 Piccoli and colleagues target a noncoding RNA to prevent cardiac remodeling.
Fibroblasts contribute to myocardial remodeling during pressure overload-induced cardiac hypertrophy. These cells secrete factors that reorganize the extracellular matrix (ECM), creating fibrosis and heart dysfunction. To learn more about the remodeling actions of cardiac fibroblasts, Piccoli and colleagues investigated the array of long noncoding RNAs (lncRNAs) produced by these cells. LncRNAs regulate a variety of cellular processes and certain lncRNAs have been implicated in cardiovascular disease. However, the roles of cardiac fibroblast lncRNAs have not been thoroughly studied. In mice with pressure-induced hypertrophy, the team identified 3 lncRNAs that were specifically dysregulated in cardiac fibroblasts. Of these, one called Meg3 was the most abundant and has previously been implicated in fibrosis. Functional studies of Meg3 revealed that the RNA, by binding and activating transcription factor p53, promotes the expression of an ECM enzyme called MMP-2. The team also showed that antisense inhibition of Meg3 could prevent the pressure-induced increase in MMP-2 as well as the associated fibrosis and hypertrophy in mice. Inhibition of Meg3 may, therefore, be an effective way to prevent cardiac fibrosis and dysfunction during heart disease, say the authors.
High Throughput Screen in Cardiomyocytes (p 604) 46 McLendon et al identify factors influencing protein aggregation within cardiomyocytes.
Accumulations of misfolded proteins within cells can impair cellular functions. Cellular aggregates of misfolded proteins are cleared mainly by the autophagic and proteasomal pathways, and this clearance is particularly important in postmitotic cells, such as those in the brain and heart. Indeed, protein aggregates are a hallmark of certain neurodegenerative disorders as well as heart conditions including desmin-related myopathy (DRM)-a disease characterized by heart and skeletal muscle degeneration.
Using a mouse cardiomyocyte model of DRM and a library of silencing RNAs, McLendon and colleagues have now carried out an unbiased genome-wide screen for novel genes that either prevent protein aggregates or promote their clearance. The team identified a number of novel candidates, including the tyrosine kinase, Jak1, whose inhibition reduced protein aggregation by at least 50%. Further analysis of Jak1 in the mouse cells revealed that knock down of the kinase increased proteosomal, but not autophagic, activity. This work not only indicates that Jak1 could be a target for promoting protein clearance in DRM and other protein aggregation diseases, but also provides a list of other protein clearance candidates worthy of consideration.
ET-1 Stimulates Vasoconstriction Through Rab11A
(p 650) 47 Zhai et al determine the intracellular mechanics of endothelin-1 induced vasoconstriction.
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Controlling contraction and relaxation of arteries involves the careful balancing of opposing vasoconstrictive and dilatory signals, which act upon the smooth muscle cells (SMCs) of the vessel walls. Ion channels that regulate both the influx and intracellular levels of calcium within SMCs control contractility, but how the vasoconstrictive and dilatory signals regulate these channels is largely unknown. To learn more, Zhai and colleagues focused on the BK channels of SMCs. They found that the vasoconstrictor endothelin-1 prevents the trafficking of an essential BK subunit (β1) to the plasma membrane of arterial SMCs, and thus diminishes BK activity. Reduced trafficking of β1 to the cell surface involved endothelin-1 activation of protein kinase C followed by phosphorylation (and inhibition) of the intracellular trafficking factor Rab11a. In contrast, nitric oxide, a potent vasodilator, activated Rab11a and promoted trafficking of β1 to the plasma membrane. The study provides insight into the mechanisms controlling arterial constriction and dilation and reveals potential targets, such as Rab11a, that might be manipulated pharmaceutically to regulate vascular contractility.
Ambient Temperature Controls Monocyte Egress
From Marrow (p 662) 48 Warm ambient temperatures reduce atherosclerosis in mice, report Williams et al.
Epidemiological data shows an association between cold temperatures and adverse cardiovascular events. Yet, cold temperatures also stimulate thermogenesis within brown and beige fat, which is thought to improve weight loss and insulin sensitivity. To gain a better understanding of the effects of ambient temperature on cardiovascular disease, Williams and colleagues housed mice that are prone to atherosclerosis in rooms where the ambient temperatures were 4ºC, 22ºC, or 30ºC. Although total plasma cholesterol levels did not differ between the 3 groups, animals housed at 4ºC had the greatest plaque burden, while those housed at 30ºC had the lowest. The ambient temperature also inversely correlated with the abundance of monocytes emerging from bone marrow and infiltrating plaques, with animals housed at 30ºC exhibiting the lowest levels of both and the lowest numbers of circulating monocytes overall. The team went on to show that monocyte counts in humans were also inversely correlated with seasonal temperature changes. Williams and colleagues argue that while activation of brown and beige fat may instigate beneficial metabolic changes for combating obesity, promoting exposure to cold as a means to achieve this end, could have adverse effects.
Genome Editing Therapy for DMD Cardiomyopathy (p 923) 49 Editing the dystrophin gene improves heart muscle function in mice with muscular dystrophy, report El Refaey et al.
Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, is caused by mutations to dystrophin-a protein essential for the structural stability of muscle cells. There is no cure for DMD and patients face a life of slowly degenerating muscles, and death normally occurs in early adulthoodmost often because of weakened heart and lung muscles. 51 Tiedt et al identify 3 microRNAs as potential biomarkers of acute ischemic stroke.
Stroke is the second most common cause of death and primary cause of long-term disability world wide. While most strokes are due to brain ischemia, others are caused by hemorrhage, and determining which form a patient has is critical for subsequent treatment. CT scans of acute stroke victims help identify the cause, but ≈40% to 50% of ischemic stroke sufferers lack detectable abnormalities. Blood-based biomarkers would, therefore, be a helpful addition to the diagnostic toolbox. Tiedt and colleagues reasoned that microRNAs (miRs), because of their stability in peripheral blood, might be informative biomarkers. Thus, they sought to identify differentially regulated miRs between patients with ischemic stroke and controls. RNA sequencing of blood samples taken from 260 acute ischemic stroke patients on the day of hospitalization revealed 3 miRs that were robustly and reproducibly upregulated in patients: miR-145-3p, miR-125b-5p, and miR-125a-5p.
The team went on to show that levels of all 3 miRs declined in the days following acute stroke. In combination, these miRs outperformed CT scans for diagnostic utility. These encouraging findings now pave the way for further studies in larger cohorts of acute ischemic stroke patients.
LKB1 and Atherosclerosis (p 1047)
52
The kinase LKB1 slows foam cell formation and atherosclerosis progression in mice, report Liu et al.
Atherosclerosis begins with the gradual accumulation of fatty deposits on blood vessel walls. Monocytes are recruited to the lesions where they convert to macrophages to phagocytose lipids in the lesions. Continued lipid uptake by the macrophages transforms them into foam cells, which is a critical step in plaque development. However, mechanisms underlying this transformation remain unclear. Liu and colleagues now show that the kinase LKB1, previously identified as having cardioprotective and anti-inflammatory effects, is a negative regulator of foam cell development. They found that, in mice prone to atherosclerosis, the levels of LKB1 in plaque macrophages decreases with disease progression. This decrease prevented LKB1-directed phosphorylation of scavenger receptor A (SRA)-a principle macrophage receptor responsible for lipid uptake and foam cell conversion.
The team went on to show that LKB1-directed phosphorylation of SRA promotes the receptor's degradation. They also found that atherogenesis was accelerated in atherosclerosisprone mice with LKB1-lacking macrophages. As in mice, levels of LKB1 are also low in humans with atherosclerosis, suggesting the kinase may have a similar role in both mice and humans. Thus, boosting LKB1 levels in macrophages might be a new way to slow or prevent the progression of atherosclerosis.
Endothelial TRPM2 in PMN Transmigration (p 1081) 53 Mittal et al examine the molecular details of neutrophil transmigration across the vascular endothelium.
Neutrophils must exit the blood to get to sites of injury or infection, and they do this by squeezing through or between the endothelial cells-a process known as transmigration. Neutrophils generated reactive oxygen species (ROS) for killing bacteria, but recent evidence suggests ROS generation may also help neutrophils exit the blood. Indeed, exposure of endothelial cells in culture to the ROS hydrogen peroxide induces the opening of interendothelial junctions. And this process was shown to require calcium entry into endothelial cells via the cation channel TRPM2. Mittal and colleagues have now investigated this TRPM2-dependent mechanism in mice. The team engineered mice with endothelium-specific conditional deletion of TRPM2 and found that, when the mice were injected with bacterial toxin, the animals exhibited reduced inflammation (fewer neutrophils exiting the blood) compared with wild-type controls. Upon examining the molecular details of TRPM2-dependent transmigration, they found that neutrophil released ROSinduced production of ADPR, a TRPM2 activator, which was essential for the channel's action. Together, these results suggest that, in cases of excessive inflammation, inhibition of TRPM2 might be an effective anti-inflammatory approach. 55 Li et al uncover an unexpected effect of protein kinase C deletion on atherosclerosis.
CV Event Prediction by
Excess lipids in the blood can activate monocytes and enhance their uptake into artery walls, thus promoting the development of atherosclerotic plaques. This lipid-induced activation of monocytes involves the signal transduction factor protein kinase C (PKC); but PKC has a number of isoforms, so exactly which enzyme is involved in the process, and how, remains unclear. To find out, Li and colleagues examined rats with hyperlipidemia. They showed that PKC levels were indeed increased in the animals' monocytes, and that most of this was accounted for by an increase in PKCδ. To determine the physiological significance of this increase, the team generated transgenic atherosclerosis-prone mice with macrophages lacking PKCδ. To their surprise, the researchers found that mice lacking PKCδ in macrophages exhibited accelerated atherosclerosis compared with controls, their plaques were larger, and contained more macrophages. Further investigations revealed that the numbers of plaque macrophages increased due to reduced apoptosis and increased proliferation of these cells, as well as to increased phosphorylation of pro-survival factors. The authors conclude that specific activation of the δ isoform of PKC in monocytes may be a way to limit atherosclerosis progression. 59 Sharp et al bring cortical bone stem cell therapy one step closer to the clinic.
CRISPR/Cas9 Postnatal
A variety of cell types have been tested in animals and patients for their potential to promote the regeneration of injured and failing hearts. Mesenchymal stem cells (MSCs) and cardiacderived progenitor cells (CDCs), for example, are among the most commonly tested cells, but while these cells have given encouraging results in animals, clinical benefits in patients remain uncertain. Stem cells derived from the cortical regionthe dense outer layer-of bone (CBSCs) have recently been shown to be more effective than CDCs at improving heart function and reducing scar size after myocardial infarction in mice. Now, Sharp and colleagues have tested these cells in a larger animal model, more comparable to human patients. After undergoing induced myocardial infarctions, a group of pigs was given transendocardial injections of allogenic CBSCs, while another group was given control injections. After 3 months, the hearts of the CBSC-treated pigs exhibited smaller infarct scars, less ventricular dilation, and better preservation of function than control pigs. Although the study did not compare CBSCs to other types of stem cells, the results warrant further investigations of CBSCs as a potential cell therapy option.
Cell Dosing in Ischemic Cardiomyopathy (p 1279) 60 Stem cell dose is critical to cell therapy outcomes, say Florea et al.
Many preclinical studies and clinical trials of cell therapies for heart disease have focused on identifying the best cell type to use, but few have focused on determining the optimal dose. Even the studies that have investigated cell dosage have given complicated and seemingly contradictory results. Given the importance of resolving questions of dosage, Florea and colleagues tested the safety and efficacy of 2 different doses of human allogenic mesenchymal stem cells (hMSCs) in 30 patients with chronic ischemic left ventricle dysfunction following myocardial infarction. Fifteen of the patients were given transendocardial injections of 20-million hMSCs, while the other 15 were dosed with 100-million cells. All patients were then followed for 12 months during which time none experienced serious adverse events. While the size of the infarct scars and the presence of systemic inflammation was shown to decrease similarly in both treatment groups, only patients in the 100-million cell group experienced improvements in left ventricle function. The results show that cell dosage is an important determinant of the clinical outcome of cell therapies and highlight the need for further trials aimed at evaluating optimal dosage.
T3+Dex
Generates Functional T-Tubules in hiPSC-CM (p 1323) 61 Parikh et al develop a protocol for promoting t-tubule formation in human iPSC-derived cardiomyocytes.
Cardiac myocytes derived from human induced pluripotent stem cells (hiPSC-CMs) are useful for modeling a variety of heart diseases and potentially for repairing injured hearts. But the process of in vitro hiPSC-CM differentiation generally fails to produce fully mature cells. For example, they tend to lack t-tubules-membranous invaginations that transverse the cell and are essential for normal cellular electrophysiology. Previous strategies for improving hiPSC-CM maturation include growing the cells on a matrix of physiological stiffness (matrigel mattress) and adding thyroid and glucocorticoid hormones to the media. However, neither of these approaches promote fully fledged t-tubule development. Parikh and colleagues have now discovered that by combining these two approaches, the iPSC-CMs could be made to develop t-tubules that are morphologically and functionally mature, ie, they display synchronized intracellular calcium release and improved excitation-contraction coupling. The new maturation approach could not only improve the production of mature cardiac myocytes for disease modeling and clinical use, say the authors, but also provide a useful tool for unravelling the molecular mechanisms of t-tubule development.
Cellular Basis of Cardiocutaneous Syndromes (p 1346) 62 Karmouch et al identify the cellular basis of cardiocutaneous syndrome, and create a mouse model of the disease in the process.
Arrhythmogenic cardiomyopathy (ACM) is characterized by ventricle arrhythmias that occur prior to cardiac dysfunction. Some patients experience palpitations, fainting, even sudden death, before any chronic heart defect is apparent. The condition is most commonly caused by mutations in desmosomes, which are cell-to-cell adhesion proteins. Homozygous mutations in the desmosomal proteins desmoplakin or plakoglobin, for example, cause cardiocutaneous syndrome, a form of ACM, in which patients have skin and hair abnormalities (including alopecia) in addition to arrhythmia. Karmouch and colleagues have identified a distinct subset of cells associated with cardiocutaneous syndrome. They found that cells expressing Cspg4 (chondroitin sulfate proteoglycan 4) are present in the skin and cardiac conduction system-and that conditional deletion of desmoplakin in Cspg4-positive cells in mice recapitulated the human symptoms of cardiocutaneous syndrome-namely arrhythmia prior to cardiac dysfunction and alopecia. This new model should aid investigations into the molecular mechanisms of the syndrome and potentially, identification of relevant therapeutic targets.
Thyroid Function and Atherosclerotic Outcomes (p 1392) 63 Increased thyroid activity may increase a person's risk of atherosclerosis, say Bano et al.
High thyroid activity has been linked to hypertension, hypercoagulation, and atrial fibrillation, whereas low thyroid activity has been linked to hyperlipidemia and inflammation. In principle, either situation could contribute to atherogenesis, but investigations into the relationship between thyroid activity and the formation of atherosclerotic lesions have given mixed results. Some studies report an increased risk with higher thyroid function, while other reports associate atherogenesis with lower thyroid function. Some studies have reported no link at all. To resolve the issue, Bano and colleagues carried out a large-scale clinical study in which 9420 subjects were followed for an average of 9 years. The study encompassed the full spectrum of atherosclerosis-from subclinical artery calcification to adverse cardiovascular events and death. They found that high levels of free thyroxine-an indicator of high thyroid activity-was associated with increased artery calcification, as well as with a higher risk of adverse events and death. The association remained significant even in the absence of other cardiovascular risk factors-such as body mass index and lipid levels-and within ranges of thyroid activity considered normal. The authors conclude that thyroxine could be a useful marker for identifying atherosclerosis patients most at risk of morbidity and mortality.
